Sarcopenia and Muscle Wasting

Sarcopenia is the progressive loss of skeletal-muscle mass, strength, and function, most often associated with ageing but also seen in chronic and acute illness. This topic explains how the condition is defined and assessed and why protein and physical activity are central to its physiology, framed as reference material rather than treatment guidance.

Definition

Sarcopenia is a progressive and generalised skeletal-muscle disorder characterised by low muscle strength together with low muscle quantity or quality, and associated with adverse outcomes such as falls, disability, and mortality.

Scope

The topic covers the definition and diagnostic criteria of sarcopenia, the distinction between low muscle mass and low muscle strength, the role of anabolic resistance and protein intake, and acute muscle wasting in critical illness. It is reference content on a clinically recognised condition and does not provide diagnostic thresholds for individual care or prescribe interventions.

Core questions

• How is sarcopenia defined, and why has muscle strength become central to its diagnosis?
• How does sarcopenia differ from cachexia and from simple disuse atrophy?
• What role do protein intake and anabolic resistance play in muscle maintenance?
• How does acute muscle wasting in critical illness relate to age-related sarcopenia?

Key concepts

• Muscle strength versus muscle mass
• Muscle quality
• Anabolic resistance
• Primary (age-related) and secondary sarcopenia
• Acute muscle wasting in critical illness
• Physical function and disability outcomes

Mechanisms

Skeletal muscle is maintained by a balance of protein synthesis and breakdown that, with ageing, shifts toward net loss as the muscle becomes less responsive to anabolic stimuli such as protein and exercise — anabolic resistance — which underpins the higher protein intakes recommended for older people (Bauer et al., 2013). The condition was named by Rosenberg to draw attention to this age-related loss (Rosenberg, 1997), and the revised European consensus reframed it around low muscle strength as the primary criterion, with low mass and poor physical performance confirming and grading severity (Cruz-Jentoft et al., 2019). Acute illness produces a faster, inflammation-driven form of muscle wasting; low muscle mass measured at intensive-care admission has been associated with worse outcomes, illustrating that wasting matters across both chronic and acute settings (Moisey et al., 2013).

Clinical relevance

Sarcopenia is recognised as a condition in its own right and is relevant to nutrition assessment, frailty, and rehabilitation. This entry describes how it is defined and why muscle mass and strength matter; it is educational reference material and is not a basis for individual diagnosis, screening decisions, or treatment.

Epidemiology

Sarcopenia becomes more common with advancing age and is frequent in older hospital, geriatric, and oncology populations; consensus definitions were developed partly to standardise how its prevalence and impact are measured (Cruz-Jentoft et al., 2019).

Evidence & guidelines

Definition and assessment rest on the revised European (EWGSOP2) consensus, which prioritises muscle strength (Cruz-Jentoft et al., 2019); related nutritional reasoning draws on the PROT-AGE protein recommendations for older people (Bauer et al., 2013).

History

Irwin Rosenberg proposed the term 'sarcopenia' in the late 1980s and elaborated its clinical relevance in 1997, giving a name to age-related muscle loss. European working groups subsequently issued operational definitions; the 2019 revision (EWGSOP2) shifted the diagnostic emphasis from muscle mass to muscle strength, reflecting evidence that strength better predicts adverse outcomes.

Debates

Should diagnosis lead with muscle mass or muscle strength?

Earlier definitions centred on low muscle mass, but the revised European consensus made low muscle strength the entry criterion because strength more strongly predicts functional decline, a reframing that changed how cases are identified.

Key figures

• Irwin Rosenberg
• Alfonso Cruz-Jentoft
• Jürgen Bauer

Seminal works

• rosenberg-1997
• cruz-jentoft-2019

Frequently asked questions

Is sarcopenia the same as cachexia?

No. Sarcopenia is loss of muscle mass and strength (often age-related), while cachexia is inflammation-driven wasting tied to an underlying disease; the two overlap but are defined differently and have distinct drivers.

Why does modern diagnosis emphasise muscle strength?

Because muscle strength predicts falls, disability, and other adverse outcomes more strongly than muscle mass alone, the revised European consensus made low strength the primary diagnostic criterion.